CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that four abstracts have been accepted for presentation, including three oral presentations, at the 25
th
Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held in Washington, D.C., and virtually, May 16 – 19, 2022. The Company is presenting data on its pipeline and platform technologies to support ongoing development programs.
Key Editas Medicine presentations at ASGCT include:
-
Preclinical data on EDIT-202 demonstrating maintained expression levels of CD16 and mbIL15, prolonged persistence in the absence of exogeneous cytokines and significantly enhanced anti-tumor efficacy in an
in vivo
solid tumor model. - Safety data from the BRILLIANCE trial of EDIT-101 demonstrating a favorable immunogenic profile.
- Preclinical data from non-human primate studies of EDIT-103, in development for the treatment of rhodopsin-associated autosomal dominant retinitis pigmentosa (RHO-adRP), demonstrating nearly 100% gene editing knockout of endogenous RHO gene and more than 30% replacement protein levels.
- Data demonstrating SLEEK (SeLection by Essential-gene Exon Knock-in) gene editing is an optimal strategy for achieving robust multi-transgene knock-in for the next generation of cell therapy medicines.
“Editas Medicine is making strong progress towards the clinic with our preclinical pipeline and in our efforts to develop transformative medicines for people living with serious diseases, including ocular diseases, hemoglobinopathies, and cancer,” said Mark S. Shearman, Ph.D., Executive Vice President and Chief Scientific Officer, Editas Medicine. “We look forward to sharing compelling data and important updates for several of our programs, including EDIT-101, EDIT-103, EDIT-202, and our SLEEK gene editing method at ASGCT later this month.”
The complete list of Editas Medicine presentations is below. Abstracts can be accessed on the
ASGCT website
, and the presentations will be posted on the
Editas Medicine website
during the conference.
Oral Presentations:
Title:
Exploratory Immuno-Safety Profile of EDIT-101, a First-in-Human
In Vivo
CRISPR Gene Editing Therapy for
CEP290
-Related Retinal Degeneration
Session Date and Time:
Monday, May 16, 2022, 1:30 p.m. – 3:15 p.m. ET
Presentation Time:
2:45 p.m. – 3:00 p.m. ET
Session title:
Gene and Cell Therapy Trials in Progress
Title:
SLEEK: A Method for Highly Efficient Knock-in and Expression of Transgene Cargos for Next-generation Cell-based Medicines
Session Date and Time:
Wednesday, May 18, 2022, 3:45 p.m. – 5:30 p.m. ET
Presentation Time:
5:00 p.m. – 5:15 p.m. ET
Session title:
New Gene Editing Technologies and Applications
Title:
A Mutation-Independent CRISPR/Cas9-Based ʻKnockout and Replaceʼ Strategy to Treat Rhodopsin-Associated Autosomal Dominant Retinitis Pigmentosa
Session
Date and Time:
Thursday May 19, 2022, 10:15 a.m. – 12:00 p.m. ET
Presentation Time:
10:15 a.m. – 10:30 a.m. ET
Session title:
Ophthalmic and Auditory Diseases
Poster Presentation:
Title:
EDIT-202, A Multiplexed CRISPR-Cas12a Gene-Edited iPSC-Derived NK Cell Therapy has Prolonged Persistence, Promotes High Cytotoxicity, and Enhances
In Vivo
Tumor Killing
Session Date and Time:
Wednesday, May 18, 2022, 5:30 p.m. – 6:30 p.m. ET
Session Title:
Cancer – Targeted Gene and Cell Therapy II
About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit
www.editasmedicine.com
.
Forward-Looking Statements
This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “target,” “should,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Company’s product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.
Contacts: Media Cristi Barnett (617) 401-0113 [email protected] Investors Ron Moldaver (617) 401-9052 [email protected]
